Tag Archives: recurrence

Race, Insurance Status, Influence Treatment of Ovarian Cancer

A study of more than 47,000 women with ovarian cancer found that uninsured and Medicaid patients were less likely to receive the standard of care. Additionally, women who were African … Continue reading 

Posted in News | Also tagged , , , , , , | Leave a comment

Avastin Shown to Slow Tumor Growth; Not Prolong Life

Two studies of the use of Avastin in ovarian cancer showed that the drug slowed tumor growth but did not improve overall survival. “While we are looking for that silver … Continue reading 

Posted in News | Also tagged , , , , , , | Leave a comment

Bilateral Oophorectomy Associated With Higher Prevalence of Low Bone Mineral Density and Arthritis in Younger Women

A study presented at a breast cancer conference showed a link between lower bone density and removal of the ovaries. Women who had both ovaries removed before 45 years of … Continue reading 

Posted in News | Also tagged , , , , | Leave a comment

Mutation in KRAS Gene May Indicate Drug Resistance in Ovarian Cancer Patients

A genetic mutation that causes a change in the KRAS pathway appears to be linked to higher likelihood of platinum resistance in women with ovarian cancer. The KRAS pathway is … Continue reading 

Posted in News | Also tagged , , , , , , | Leave a comment

Another Ovarian Cancer Vaccine Trial Approved

MXi Pharmaceuticals has recieved approval to begin a trial for ovarian/uterine cancer. The company hopes to start enrolling patients this calendar year. See the news release here Enroll in clinical … Continue reading 

Posted in News | Also tagged , , | Leave a comment

PAPR Inhibitors May Work Against More Ovarian Cancers

PAPR inhibitors, first used in trials for women with ovarian cancer who had a mutation in the BRCA1 or BRCA2 gene, are now being used in trials for women without … Continue reading 

Posted in News | Also tagged , , , , , | Leave a comment

Phase II Trial of Phenoxodial Complete

INTRODUCTION: Chemoresistance is a major limitation in the treatment of ovarian cancer. Phenoxodiol is a novel biomodulator capable of reversing chemoresistance in vitro and in vivo. In this study, we … Continue reading 

Posted in News | Also tagged , , | Leave a comment

Girls with ovarian germ-cell tumors can safely skip chemotherapy unless disease recurs, new study suggests

Researchers from Dana-Farber/Children’s Hospital Cancer Center (DF/CHCC) have found that as many as 50 percent of young girls treated for germ-cell ovarian tumors might safely be spared chemotherapy using a … Continue reading 

Posted in News | Also tagged , , , | Leave a comment

New Clues to Treating Ovarian Cancer Relapse

Starting chemotherapy when first signs reappear not especially effective, study finds New research finds that women with ovarian cancer relapse who start chemotherapy as soon as levels of a biomarker … Continue reading 

Posted in News | Also tagged , | Leave a comment

Cancergazing? CA125 and post-treatment surveillance in advanced ovarian cancer.

Post-treatment surveillance of advanced ovarian cancer involves regular testing of asymptomatic patients using the CA125 test. This practice is based on a rationale that is not supported by evidence from … Continue reading 

Posted in News | Leave a comment

Recurrent Ovarian Cancer: Use of Contrast-enhanced CT and PET/CT to Accurately Localize Tumor Recurrence and to Predict Patients’ Survival

Purpose: To compare accuracy and interobserver variability in the detection and localization of recurrent ovarian cancer with contrast material–enhanced (CE) computed tomography (CT) and positron emission tomography (PET)/CT and determine … Continue reading 

Posted in News | Also tagged , | Leave a comment

“Shielded” ovarian cancer cells may survive chemotherapy

Monday 28 June 2010 Cancer Research UK Press Release “SHIELDED” OVARIAN CANCER CELLS MAY SURVIVE CHEMOTHERAPY TO RE-GROW TUMOUR Cancer Research UK scientists have discovered certain ovarian tumour cells that … Continue reading 

Posted in News | Also tagged , | Leave a comment